TickerTalks
Browse all tickers →
TickerTalks›$MEDP
MEMEDP

Medpace Holdings, Inc.

$MEDP·$17B·Medical - Diagnostics & Research·Healthcare
$601.38-0.7%YTD+7.6%1Y+32.0%
Mentions · last 7 days
2026-07-18: 0 posts2026-07-19: 5 posts2026-07-20: 4 posts2026-07-21: 7 posts2026-07-22: 68 posts2026-07-23: 196 posts2026-07-24: 12 posts292
Price updated 13h ago·X counts updated 14h ago
MEMEDP
$MEDPMedpace Holdings, Inc.
$601.38-0.73%292 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $MEDP, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersCooling offAI verdict · as of 2026-07-25

Catching its breath after a run — could pick back up or fade from here.

The specialty CRO with an unusually high ROIC is quietly running with no X noise — the print is a real reset event.

Medpace is a specialty contract research organisation focused on running clinical trials for small- and mid-cap biotech clients. Up 7.6% year to date and 32% over 12 months at 75% of its 52-week range with earnings on October 28, this is a name where the fundamentals stand alone with no meaningful X sentiment to fight against.

Why the business is genuinely elite:

  • The return profile is unusual for the sector: trailing ROIC of 77% is best-in-class for a CRO — that reflects a very focused specialty-biotech client base plus tight operational control, and is what supports the 35x trailing P/E vs a broader CRO peer group in the mid-20s.
  • The growth remains solid: last quarter revenue grew 17% YoY to $709M with gross margin of 29% and operating margin of 21% — those are healthy CRO numbers, and the delta versus IQV or the Thermo CRO segment is Medpace's specialty-biotech focus rather than pharma-service breadth.
  • The cyclical exposure is the real risk: as a specialty-biotech CRO, Medpace is directly exposed to biotech-funding cycles — a softening in biotech IPO or private-market activity flows straight through to bookings, which is why the trajectory reads 'cooling' rather than 'accelerating' despite the strong operating profile.

The October 28 print is the reconciliation event: revenue growth holding above 15% plus specific commentary on backlog stability and biotech-client bookings is what continues the trend. Any softening of the backlog or specific commentary that biotech-client cancellation rates are picking up is what breaks the setup and validates the trajectory read — that combination would take the multiple back toward the CRO-peer average and give back much of the year-to-date gain.

What to watch: October 28 Q3 earnings: revenue growth trajectory above 15%, backlog stability, and biotech-client cancellation-rate commentary — a backlog softening or cancellation-rate pickup takes the multiple back to the CRO-peer average.

On the calendar: 2026-10-28 — Q3 2026 earnings

no sentiment data

Read the AI verdict + X sentiment for $MEDP

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $MEDP.

Medical - Diagnostics & Research · Healthcare

No material change from last week — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials.

Industry benchmark

16-name peer basket
+27.5%YTD
+48.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
34.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
77.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
110%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
28.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 22, 2026$4.25$3.98+6.8%
Q1 2026Apr 22, 2026$4.28$3.92+9.2%
Q4 2025Feb 9, 2026$4.67$4.19+11.5%
Q3 2025Oct 22, 2025$3.86$3.53+9.3%
Next earningsWed, Oct 28·consensus EPS $4.41

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$707.3M+17.2%28.5%20.8%$4.31$168.8M
Q1 FY26$706.6M+26.5%27.8%20.0%$4.35$145.0M
Q4 FY25$708.5M+32.0%29.0%21.6%$4.78$188.1M
Q3 FY25$659.9M+23.7%29.8%21.5%$3.95$262.3M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.8B$2.8B – $2.9B$17.54$17.29 – $17.877
FY27$3.0B$2.8B – $3.3B$19.33$18.12 – $20.069
FY28$3.3B$3.1B – $3.4B$21.51$20.36 – $22.929
FY29$3.4B$3.3B – $3.6B$23.65$22.45 – $24.864
FY30$3.8B$3.6B – $3.9B$25.61$24.31 – $26.934

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.75%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+23.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 22.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.155-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 28Stephen P EwaldGeneral Counsel & Corp. Secy.16.3K sh$7.4MSellMar 17Jesse J GeigerPresident31.7K sh$14.4M
+ 23 other (13 exempts · 10 awards) in window

See when $MEDP insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 43
AI summary

Hansman Brad W. filed an initial Form 3 as a 10%+ owner of MEDP, disclosing initial beneficial ownership of securities as of the event date. This is a standard Section 16 reporting obligation triggered by the relationship with the issuer. Routine administrative filing with no indication of open-market transactions.

8-KOfficer or director changeJun 48-K — Item 5.02: Officer or director change
AI summary

MEDP filed an 8-K under Item 5.02 disclosing a personnel change: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Personnel changes are typically administrative but can signal strategic shifts depending on context.

8-KCharter amendmentMay 198-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
8-KOfficer or director changeApr 228-K — Item 2.02: Earnings release · Item 5.02: Officer or director change
+ 10 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?zacks.com·1d agoMedpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlookbenzinga.com·2d agoMedpace: 'Buy' On Financial Metric Improvements And Solid Q2 2026 Earningsseekingalpha.com·2d agoMedpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcriptseekingalpha.com·2d agoMedpace Q2 Earnings Call Highlightsmarketbeat.com·2d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$DHR$TMO$PSNL$CDNA$TWST$A$ILMN$STIM
Voices on X · top 10 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport